Nutriband Inc (NTRB)

$NTRB News: Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference

Nutriband’s Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference

Company to Meet with Buyers from Walmart Inc, Walgreens, Amazon.com, Inc., Cardinal Health and Other Major National Retailers

ORLANDO, Fla., May 15, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) and its wholly owned subsidiary Active Intelligence (“Active Intelligence” or the “Company”), an emerging leader in innovative wellness, recovery, and performance-focused consumer products, today announced its participation in the upcoming ECRM conference taking place in June 2026, where the Company will showcase its latest AI-branded product portfolio to buyers and executives from some of the nation’s largest retail and healthcare organizations.

During the conference, Active Intelligence is scheduled to meet with category buyers and decision-makers representing major national retailers and distributors, including Walmart, Walgreens, Amazon, Cardinal Health, and numerous additional retail, pharmacy, healthcare, and e-commerce channels.

The Company will feature its growing AI Tape product line, which continues to gain traction within the wellness, recovery, and athletic performance categories. In addition, Active Intelligence plans to introduce several new products scheduled for launch in June 2026, including:

AI Performance Tape — a next-generation kinesiology and recovery product designed to support athletic performance, mobility, muscle recovery, and active lifestyles;
AI Energy Patches — innovative wearable wellness patches formulated to support energy, focus, and daily performance; and
AI Sleep — a wellness-focused solution developed to support relaxation, recovery, and improved sleep quality.
The Company believes these new additions further strengthen its position within the rapidly expanding global wellness market and broaden its opportunities for national retail placement across multiple high-growth consumer categories.

“We are excited to meet directly with some of the world’s largest retailers and healthcare distributors to showcase our growing AI product platform. Consumer demand for wellness, recovery, energy, and performance solutions continues to accelerate, and we believe Active Intelligence is uniquely positioned to capitalize on these long-term market trends” said Gareth Sheridan, CEO of Nutriband Inc.

The ECRM conference serves as one of the leading business development and category planning events connecting consumer brands with major retailers, distributors, and pharmacy chains across North America. Management believes the Company’s participation will support ongoing discussions related to new retail partnerships, expanded distribution opportunities, and future product placement initiatives.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

https://www.globenewswire.com/newsroom/ti?nf=OTcyMTA0MSM3NjA1MzcwIzIyOTY3OTk=
https://ml.globenewswire.com/media/ZDA5MGY3MjAtYmIyOC00Y2Q1LTg2NDEtMTJiZGRjNGJmMzM4LTEzMDgzNDktMjAyNi0wNS0xNS1lbg==/tiny/Nutriband-Inc-.png

Source: Nutriband Inc.

$NTRB News: Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company’s AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications.

Interested shareholders may find the link to the latest youtube episode here .

The Episode can also be found on Spotify, iTunes, Amazon music and www.jackneel.com

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

https://www.globenewswire.com/newsroom/ti?nf=OTY5NDQ1OSM3NTQ4NDk1IzIyOTY3OTk=
https://ml.globenewswire.com/media/MDA5ZDVkMjYtYzUwYS00MTc4LTk2ZjEtMjE4ZTdhZWZmY2Q1LTEzMDgzNDktMjAyNi0wNC0yMi1lbg==/tiny/Nutriband-Inc-.png

Source: Nutriband Inc.

I know nothing. But it seems like this turkey did not make one of it's normal 4 to 5 dollar runs in a long time. I am getting the feeling that between now and May first, it is going to run 8 to 10 bucks. At least I hope so. I got more of it than I need.

Very few people realize how big a deal this Earth Vision Bio is. Were talking a company that is going to disrupt major markets as we now know them. Until they have their own stock listed, this is the only way to get on board. Not sure, but the way I read it. NTRB's 10 percent will never be diluted. Check out the website of EARTH VISION BIO. This will be a stock for people younger than me to own.

This site is as dead as my HERMAN, and he's been dead for 40 years.

So, NTRB becomes a back door to Earth Vision Bio. Which has some high quality names in it. The deal gives Earth vision Bio more than enough owners of the stock to get listed on the New York exchange. While NTRB gets enough money to complete their product development. If the government outlaws the sale of fentanyl in pill form. The only legal use of it would be in Nutriband's products. Interesting.

Help I have fallen and can't get up.

I wish I knew why I am still here and adding.

With a name like, Sweet crude. I would think I would of seen you at AZRH.

Video on NTRB Fentanyl delivery system

NTRB, reports 10Q Friday, 09/05

Signal Update
Our system’s recommendation today is to BUY. The BULLISH INVERTED HAMMER pattern finally received a confirmation because the prices crossed above the confirmation level which was at 6.9500, and our valid average buying price stands now at 7.0200. The previous SELL signal was issued on 02/05/2025, 14 days ago, when the stock price was 7.3000. Since then NTRB has fallen by -3.84%.
Market Outlook
We may be at a market bottom or at the start of a reaction rally. Let’s jump on our white horses and go for a bullish ride. Today’s candlestick has a white body and its close is above the confirmation level. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.

Anyone have any idea why this is moving?

Must have been an interesting webinar….double the volume and down 8%.

NTRB new 52 week high

Now I’m told “it’ll “ happen 4q 2025….
More baloney….

Now I’m told “it’ll “ happen 4q 2025….
More baloney….

Typical ntrb day…

Solid day

Wowser! I happen to agree with you.

It’s under $5 for a reason. Management is just using this company as a lifestyle paycheck.

NTRB under $5

NTRB under $5

NTRB................................https://stockcharts.com/h-sc/ui?s=NTRB&p=W&b=5&g=0&id=p86431144783

NTRB....MONSTER

NTRB...GAPPING INTO OPEN FOR THE SELL

NTRB...................................https://stockcharts.com/h-sc/ui?s=NTRB&p=W&b=5&g=0&id=p86431144783

NTRB....PRE TO OPEN BEAST

$NTRB 2.95. Nice buys.

This will be at a $1.50 by the end of the week. Management sure sold me on this one!

You’d think it price would reflect news like this. They have to get rid of the word “fentanyl”. It’s so toxic. It’s right up there with ephedrine and OxyContin.

Nice news!

https://www.accesswire.com/785775/nutriband-announces-issuance-of-us-patent-for-transdermal-abuse-deterrent-technology

I sold everything, I just check back from time to time. I think they are now just using their money for salaries. Their model has the word “fentanyl” in it which is about as toxic as the word “OxyContin”.

What’s going on with this stock?

Ollie Ollie unkenfraz

What lurks behind the curtain!

Registration withdraw low float

NTRB dead cat and the down trend resumes?

What’s with the huge selling? Seems like big ask

Bid and ask tight. Volume coming in.

Agreed. Once the selling stop perhaps it will rebound back .

It could. But being out of money is going to make things tough. They definitely need something good to happen for this to pop.

I’m not sure it’s going to hit that low before a nice bounce back. It’s still a low float stock.

I personally see it at $1. Their revenue comes from k tape that you can get off of Amazon for $5. Their hope is this fentanyl patch. But even if they get approval? I don’t see many Drs wanting to prescribe it, nor patients wanting it. Let’s put it this way; if a dr asked you if you wanted traditional pain meds or a fentanyl patch; what would you want?

Where’s bottom? Should be close for a bounce hopefully.

It’s like 7.5m outstanding, but now doing an offering of $4m with a market cap of $15m, just simply means they are out of money. This isn’t looking good. I just wish they would change the name to something like “drug deterrent patch” or something. Who would want to keep an investment in fentanyl? That’s a word right up there with OxyContin???

Wasn’t there an offering for $4 mill minus underwriting fees?
I don’t remember the volume being that high. Isn’t that around 1.5 million shares sold.

“Our common stock is traded on the NASDAQ Capital Market under the symbol “NTRB. On June 22, 2023, the last reported sale price of our common stock was $2.48 per share.”

Dang, they get a patent approved and now it’s tanking. This will give you an idea of how solid their model is.

Why so much volume today?

New 52 week lows geez. What’s going on?